Halozyme


MLV Boosts Price Target For Halozyme; Increased Confidence In PEGPH20’s Mechanism

In a research report issued today after market close, MLV & Co. analyst Arlinda Lee reiterated a Buy rating on shares of Halozyme Therapeutics, Inc.

MLV Raises Halozyme Therapeutics Price Target On The Back Of Positive Interim Phase 2 Data And Additional Catalysts

In a research report sent to investors this morning, MLV analyst Arlinda Lee maintained a Buy rating on Halozyme Therapeutics (NASDAQ:HALO), and raised her …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts